Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Arbutus Biopharma Corporation (NASDAQ: ABUS)
ABUS Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
7.70%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
14.90%
ABUS Stock Analysis
ABUS
PE Ratio:
5.2
ABUS
PEG Ratio:
Not Available
ABUS
Forward EPS Growth (12 month):
0.00%
ABUS
PS Ratio:
4.5
ABUS
PSG Ratio:
ABUS
Forward Revenue Growth (12 month):
239.70%
ABUS Articles
No data was found